Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Healthequity (HQY) EBIAT (2016 - 2026)

Healthequity has reported EBIAT over the past 14 years, most recently at $49.7 million for Q1 2026.

  • For Q1 2026, EBIAT rose 88.66% year-over-year to $49.7 million; the TTM value through Jan 2026 reached $215.2 million, up 122.54%, while the annual FY2026 figure was $215.2 million, 122.54% up from the prior year.
  • EBIAT for Q1 2026 was $49.7 million at Healthequity, down from $51.7 million in the prior quarter.
  • Over five years, EBIAT peaked at $59.9 million in Q3 2025 and troughed at -$32.8 million in Q1 2022.
  • A 5-year average of $18.2 million and a median of $14.7 million in 2023 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: tumbled 711.48% in 2022 and later soared 12714.35% in 2024.
  • Year by year, EBIAT stood at -$1.6 million in 2022, then skyrocketed by 994.15% to $14.7 million in 2023, then crashed by 61.13% to $5.7 million in 2024, then surged by 806.4% to $51.7 million in 2025, then dropped by 3.78% to $49.7 million in 2026.
  • Business Quant data shows EBIAT for HQY at $49.7 million in Q1 2026, $51.7 million in Q4 2025, and $59.9 million in Q3 2025.